JP2017509683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509683A5 JP2017509683A5 JP2016560799A JP2016560799A JP2017509683A5 JP 2017509683 A5 JP2017509683 A5 JP 2017509683A5 JP 2016560799 A JP2016560799 A JP 2016560799A JP 2016560799 A JP2016560799 A JP 2016560799A JP 2017509683 A5 JP2017509683 A5 JP 2017509683A5
- Authority
- JP
- Japan
- Prior art keywords
- azetidin
- quinazoline
- ethylamino
- trifluoromethyl
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940125497 HER2 kinase inhibitor Drugs 0.000 claims 6
- HXAUJHZZPCBFPN-QGZVFWFLSA-N 4-[[(1s)-2-(azetidin-1-yl)-1-[4-chloro-3-(trifluoromethyl)phenyl]ethyl]amino]quinazoline-8-carboxamide Chemical compound C([C@@H](NC1=C2C=CC=C(C2=NC=N1)C(=O)N)C=1C=C(C(Cl)=CC=1)C(F)(F)F)N1CCC1 HXAUJHZZPCBFPN-QGZVFWFLSA-N 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461974765P | 2014-04-03 | 2014-04-03 | |
| US61/974,765 | 2014-04-03 | ||
| PCT/EP2015/000525 WO2015149909A1 (en) | 2014-04-03 | 2015-03-09 | Combinations of cancer therapeutics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509683A JP2017509683A (ja) | 2017-04-06 |
| JP2017509683A5 true JP2017509683A5 (enExample) | 2018-04-19 |
| JP6629753B2 JP6629753B2 (ja) | 2020-01-15 |
Family
ID=52692591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016560799A Active JP6629753B2 (ja) | 2014-04-03 | 2015-03-09 | がん治療剤の組合せ |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9980966B2 (enExample) |
| EP (1) | EP3125935B1 (enExample) |
| JP (1) | JP6629753B2 (enExample) |
| KR (1) | KR102410696B1 (enExample) |
| CN (1) | CN106456752B (enExample) |
| AR (1) | AR099931A1 (enExample) |
| AU (1) | AU2015240094B2 (enExample) |
| CA (1) | CA2944573C (enExample) |
| ES (1) | ES2768900T3 (enExample) |
| IL (1) | IL248126A0 (enExample) |
| MX (1) | MX370540B (enExample) |
| NZ (1) | NZ725361A (enExample) |
| RU (1) | RU2733401C2 (enExample) |
| SG (1) | SG11201608189WA (enExample) |
| WO (1) | WO2015149909A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023551408A (ja) * | 2020-11-16 | 2023-12-08 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | がん処置のためのキナーゼインヒビター組み合わせ |
| WO2025168601A1 (en) * | 2024-02-05 | 2025-08-14 | Evexta Bio | Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| US7547794B2 (en) | 2003-04-03 | 2009-06-16 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| JP2007507531A (ja) | 2003-09-30 | 2007-03-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| JP4800216B2 (ja) | 2003-10-24 | 2011-10-26 | エグゼリクシス， インコーポレイテッド | ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法 |
| PT1687305E (pt) | 2003-11-21 | 2008-10-17 | Novartis Ag | Derivados de 1h-imidazoquinolina como inibidores de proteína quinase |
| ATE447957T1 (de) | 2003-12-09 | 2009-11-15 | Us Gov Health & Human Serv | Verfahren zur unterdrückung einer immunantwort oder zur behandlung von proliferativen erkrankungen |
| JP5213229B2 (ja) | 2004-04-23 | 2013-06-19 | エグゼリクシス， インコーポレイテッド | キナーゼ調節因子および使用方法 |
| JP5274842B2 (ja) | 2004-12-28 | 2013-08-28 | エグゼリクシス， インコーポレイテッド | 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物 |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
| WO2006136821A1 (en) | 2005-06-22 | 2006-12-28 | Astex Therapeutics Limited | Pharmaceutical compounds |
| CN101300029A (zh) * | 2005-11-04 | 2008-11-05 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| HRP20141239T1 (xx) | 2009-02-11 | 2015-03-13 | Merck Patent Gmbh | Novi amino azaheterocikliäśki karboksamidi |
| AU2011254557B2 (en) | 2010-05-20 | 2015-09-03 | Ablynx Nv | Biological materials related to HER3 |
| UA110113C2 (xx) | 2010-07-29 | 2015-11-25 | Біциклічні азагетероциклічні карбоксаміди | |
| EP2643313B9 (en) * | 2010-11-24 | 2017-02-22 | Merck Patent GmbH | Quinazoline carboxamide azetidines |
| KR20150124957A (ko) * | 2013-03-11 | 2015-11-06 | 메르크 파텐트 게엠베하 | 키나아제 활성의 조절인자로서 (6-[4-1h-이미다졸-2-일)피페리딘-1-일]피리미딘-4-아민 유도체 |
-
2015
- 2015-03-09 NZ NZ725361A patent/NZ725361A/en unknown
- 2015-03-09 CN CN201580018245.XA patent/CN106456752B/zh active Active
- 2015-03-09 ES ES15710714T patent/ES2768900T3/es active Active
- 2015-03-09 MX MX2016012825A patent/MX370540B/es active IP Right Grant
- 2015-03-09 US US15/128,045 patent/US9980966B2/en active Active
- 2015-03-09 KR KR1020167030676A patent/KR102410696B1/ko active Active
- 2015-03-09 WO PCT/EP2015/000525 patent/WO2015149909A1/en not_active Ceased
- 2015-03-09 RU RU2016143153A patent/RU2733401C2/ru active
- 2015-03-09 EP EP15710714.5A patent/EP3125935B1/en active Active
- 2015-03-09 AU AU2015240094A patent/AU2015240094B2/en active Active
- 2015-03-09 JP JP2016560799A patent/JP6629753B2/ja active Active
- 2015-03-09 CA CA2944573A patent/CA2944573C/en active Active
- 2015-03-09 SG SG11201608189WA patent/SG11201608189WA/en unknown
- 2015-04-01 AR ARP150100982A patent/AR099931A1/es unknown
-
2016
- 2016-09-29 IL IL248126A patent/IL248126A0/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
| CY1123260T1 (el) | Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου | |
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| PH12018500212A1 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| EA201890654A1 (ru) | Терапевтические композиции для лечения вируса иммунодефицита человека | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| CY1119886T1 (el) | Μεθοδος βιομηχανικης κατασκευης μιας φαρμακευτικης συνθεσης στην μορφη δισκιων παρατεταμενης απελευθερωσης που περιεχουν πιρφενιδονη και χρηση αυτων στην υποστροφη χρονιας νεφρικης ανεπαρκειας, καψικης συσπασης μαστου και ηπατικης ινωσης σε ανθρωπους | |
| EA201891103A1 (ru) | Композиции для лечения спинальной мышечной атрофии | |
| EA202090486A3 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| JP2017530983A5 (enExample) | ||
| EA201992116A1 (ru) | Фармацевтические составы флороглюцинола и триметилфлороглюцинола | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| EA202191239A1 (ru) | Соединения и их применение для лечения дефицита 1-антитрипсина | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| WO2012116176A3 (en) | Asymmetric ureas and medical uses thereof | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| JP2016515550A5 (enExample) | ||
| EA201792237A1 (ru) | Фармацевтические составы | |
| WO2016015798A9 (en) | Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population | |
| EA202090398A1 (ru) | Фармацевтическая композиция, включающая сакубитрил и валсартан | |
| JP2017509683A5 (enExample) | ||
| JP2014509637A5 (enExample) | ||
| JP2015509917A5 (enExample) |